Back to search

Article

Mutation mapping of PD-L1 expression in advanced non-small cell lung cancer: A real-world retrospective cohort study

2023-08-24

Abstract excerpt

<h4>Background: </h4> The duration of response to immune checkpoint inhibitors (ICIs) varies because of tumor immune heterogeneity and employing programmed death receptor ligand 1 (PD-L1) expression to evaluate the efficacy of anti-programmed cell death-1 (PD-1)/PD-L1 antibodies remains controversial. Experimental Design A total of 138 advanced non-small cell lung cancer (NSCLC) patients subdivided into 2 groups -...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
5c17fbdc-586f-53f9-88b8-2e9a220da1d7
DOI
10.21203/rs.3.rs-3231633/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Mutation mapping of PD-L1 expression in advanced non-small cell lung cancer: A real-world retrospective cohort studyDOI 10.21203/rs.3.rs-3231633/v1
In-Depth Genomic Characterization of Programmed Cell Death Ligand 1 (PD-L1) Expression in Chinese Lung Adenocarcinoma PatientsSemantic proximity
Who Will Benefit Most From PD-L1 Detection and Immunotherapy in Non-small Cell Lung Cancer?Semantic proximity
Current Immunotherapeutic Strategies Targeting the PD-1/PD-L1 Axis in Non-Small Cell Lung Cancer with Oncogenic Driver Mutations.Semantic proximity
The association of genomic alterations with PD-L1 expression in Chinese patients with EGFR/ALK wild-type lung adenocarcinoma and potential predictive value of Hippo pathway mutations to immunotherapy.Semantic proximity
Clinicopathological and molecular characteristics associated with PD-L1 expression in non-small cell lung cancer: a large-scale, multi-center, real-world study in China.Semantic proximity
Tailoring Therapeutic Strategies in Non-Small-Cell Lung Cancer: The Role of Genetic Mutations and Programmed Death Ligand-1 Expression in Survival OutcomesSemantic proximity
Tumor mutation burden and immunological, genomic, and clinicopathological factors as biomarkers for checkpoint inhibitor treatment of patients with non-small-cell lung cancer.Semantic proximity
Study on PD-L1 Expression in NSCLC Patients and Related Influencing Factors in the Real World.Semantic proximity
Correlation between immunotherapy biomarker PD-L1 expression and genetic alteration in patients with non-small cell lung cancer.Semantic proximity
[Study Progression on Non-small Cell Lung Cancer with EGFR Mutation Treated by Immune Checkpoint Inhibitors].Semantic proximity
Research progress of biomarkers in the prediction of anti-PD-1/PD-L1 immunotherapeutic efficiency in lung cancer.Semantic proximity
Association of PD-L1 expression with driver gene mutations and clinicopathological characteristics in non-small cell lung cancer: A real-world study of 10 441 patients.Semantic proximity
Select a neighboring publication to make it the new centre.